Member Login
  1. Stocks
    2. /
  2. Bausch Health Companies Inc. (NYSE: BHC)
    3. /

NYSE:BHC (Bausch Health Companies Inc.)

About BHC

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.
Financial Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Bausch Health Companies Inc. (NYSE: BHC) Latest News

    The Motley Fool
    Investing

    Has Valeant Pharmaceuticals Intl Inc. Hit the Bottom?

    | Demetris Afxentiou

    With long-time investors dropping Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), questions remain: has the stock truly hit the bottom, and can…

    Read more »

    The Motley Fool
    Investing

    Bill Ackman Throws in the Towel on Valeant Pharmaceuticals Intl Inc.

    | Joey Frenette

    Bill Ackman finally dumped his entire stake in Valeant Pharmaceutical Intl Inc. (TSX:VRX)(NYSE:VRX). If you haven't already, you should probably…

    Read more »

    The Motley Fool
    Investing

    Billionaire Bill Ackman Just Sold Valeant Pharmaceuticals Intl Inc.: Should You Sell Too?

    | Nelson Smith

    Bill Ackman just sold 27.2 million Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares. Should you sell too, or does this move…

    Read more »

    caution
    Investing

    3 Red Flags That Signal it’s Time to Sell: Learning From the Past

    | Karen Thomas, MSc, CFA

    The lessons investors can learn from Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), Sierra Wireless, Inc. (TSX:SW)(NASDAQ:SWIR), and Ballard Power Systems Inc.…

    Read more »

    The Motley Fool
    Investing

    Why Shares of Valeant Pharmaceuticals Intl Inc. Plunged Yet Again

    | Karen Thomas, MSc, CFA

    Debt refinancing reminds investors of continuing trouble at Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Is the Reward Worth the Risk?

    | Jacob Donnelly

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has a plan to get out of debt, but it's going to take pristine execution.

    Read more »

    The Motley Fool
    Investing

    Another Cut for Valeant Pharmaceuticals Intl Inc.

    | Ryan Goldsman

    With another disappointing earnings release, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) may be yet another case of death by a thousand…

    Read more »

    The Motley Fool
    Investing

    Stay Away From Valeant Pharmaceuticals Intl Inc.

    | Karen Thomas, MSc, CFA

    Investors: stop dreaming of a comeback. Just stay away from Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

    Read more »

    The Motley Fool
    Investing

    Are We Witnessing the Resurgence of Valeant Pharmaceuticals Intl Inc.?

    | Demetris Afxentiou

    As Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) prepares to release a new drug to the market, the company still has a…

    Read more »

    The Motley Fool
    Investing

    Is Valeant Pharmaceuticals Intl Inc. “Investable?”

    | Alexander John Tun

    Debt and scandal aside, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) might very well be a very good contrarian investment thanks to…

    Read more »

    The Motley Fool
    Investing

    What Could Go Right for Valeant Pharmaceutical Intl Inc.?

    | Joey Frenette

    What if Joseph Papa can turn Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) around?

    Read more »

    Investing

    Valeant Pharmaceuticals Intl Inc. Crushed by Citron Research: Find Out Who’s Next

    | Chris MacDonald

    Andrew Left of Citron Research has another top pick for short-sellers looking for another opportunity to capitalize on accounting manipulations…

    Read more »